Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

Journal of Clinical Oncology

Volumn 11, Issue 4, 1993, Pages 607-615

  Kelly, Wm Kevin ^b   Scher, Howard I ^a   Mazumdar, Madhu ^b   Vlamis, Vaia ^b   Schwartz, Morton ^b   Fossa, Sophie D ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; HEMOGLOBIN; LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; DISEASE SEVERITY; HEMOGLOBIN DETERMINATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; DIETHYLSTILBESTROL; FLUTAMIDE; HORMONES; HUMAN; MALE; MIDDLE AGE; ORCHIECTOMY; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL RATE;

EID: 0027511899     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1993.11.4.607     Document Type: Article

References (25)

1. Berry WR, Laszlo J, Cox E, et al: Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer 44: 763-775, 1979
2. Petrylak DP, Scher HI, Li Z, et al: Prognostic factors for survival in patients with hormone refractory bidimensionally measurable metastatic prostatic carcinoma treated with single agent chemotherapy. Cancer 70:2870-2878, 1992
3. Scher HI, Yagoda A: Clinical trials in prostatic cancer: Methodology and controversies, in Bruce AW, Trachtenberg J (eds): Adenocarcinoma of the Prostate. New York, NY, Springer-Verlag, 1987, pp 197-220
4. Yagoda A: Cytotoxic agents in prostate cancer: An enigma Semin Urol 1:311-321, 1983
5. Wang MC, Papsidero LD, Kuriyama M. et al: Protate antigen A new potential marker for prostate cancer. Prostate 2:89-96, 1981
6. Stamey TA, Kabalin JN: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. J Urol 141:1070-1075, 1989
7. Carter HB, Partin AW, Epstein JI. et al: The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer. J Urol 144:1167-1171, 1990
8. Pontes JE, Chu TM, Slack N. et al: Serum prostatic antigen measurement in localized prostatic cancer: Correlation with clinical course. J Urol 128:1216-1218, 1982
9. Ritter MA, Messing EM, Shanahan TG. et al: Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol 10:1208-1217, 1992
10. Killman CS, Yang N, Emrich LJ, et al: Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 and D1 prostate cancer. Cancer Res 45:886-891, 1985
11. Stamey TA, Kabalin JN, Ferrari M: Prostate specific antigen in the diagnosis and treatment of the prostate. III. Radiation treated patients. J Urol 141:1084-1087, 1989
12. Ahmann FR, Marx P, Ahmann M, et al: Predicting response to therapy in metastatic prostate cancer with serial prostate specific (PSA) levels. Proc Am Soc Clin Oncol 9:134, 1990 (abstr)
13. Arai Y, Yoshiki T, Yoshida O: Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer. J Urol 144:1415-1419, 1990
14. Ferro MA, Gillatt D, Symes MO, et al: High-dose intravenous estrogen therapy in advanced prostatic carcinoma: Use of prostate-specific antigen to monitor response. Urology 34:134-138, 1989
15. Steinberg GD, Epstein JI, Piantadosi S, et al: Management of stage D1 adenocarcinoma of the prostate: The Johns Hopkins experience 1974 to 1987. J Urol 144:1425-1432, 1990
16. Fossa SD, Hosbach G, Paus E: Flutamide in hormone-resistant prostatic cancer. J Urol 144:1411-1414, 1990
17. Seidman AD, Scher HI, Petrylak D, et al: Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial endpoint in hormone-refractory prostatic cancer. J Urol 147:931-934, 1992
18. Scher HI, Curley T, Yeh S, et al: Therapeutic alternatives for hurmone-refractory prostatic cancer. Semin Urol 10:55-64, 1992
19. La Rocca RV, Danesi R, Cooper MR, et al: Effect of suramin on human prostate cancer cells in vitro. J Urol 145:393-398, 1991
20. Scher HI, Curley T, Geller N, et al: Trimetrexate in prostatic cancer: Preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-atractory disease. J Clin Oncol 8:1830-1838, 1990
21. Gleave ME, Hsieh JT, Wu HC, et al: Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors, Cancer Res 52:1598-1605, 1992
22. Qiu SD, Young CY, Bilhartz DL, et al: In situ hybridization of prostate-specific antigen mRNA in human prostate. J Urol 144: 1550-1556, 1990
23. Stein BS, Vangore S, Petersen RO: Immunoperoxidase localization of prostatic antigens. Urology 24:146-152, 1984
24. Manni A, Bartholomew M, Caplan R, et al: Androgen priming and chemotherapy in advanced prostate cancer: Evaluation of determinants of clinical outcome. J Clin Oncol 6:1456-1466, 1988
25. Emrich LJ, Priore RL, Murphy GP, et al: Prognostic factors in patients with advanced stage prostate cancer. Cancer Res 45:5173-5179, 1985